| Today’s Big NewsJan 9, 2024 |
|
Tuesday, January 23, 2024 | 11am ET / 8am PT Join a cutting-edge conversation on January 23, 2024 with Real Chemistry and Quid as they explore how their partnership has forged a deeper understanding of patient insights. Register now.
|
|
| By Angus Liu While some Merck & Co. investors may still get the heebie-jeebies when thinking about Keytruda’s patent cliff in 2028, but the company’s CEO Rob Davis now thinks “it’s just another year.” |
|
|
|
By Max Bayer Novartis’ R&D chief Fiona Marshall, Ph.D., says the company has been “pretty aggressive and active” in neuroscience-focused business development, looking for a boost to one of the company’s four key therapeutic pillars. |
By Conor Hale 2023 was a banner year for Dexcom. Not only did it undertake a new major product launch, but it received the largest expansion of insurance coverage in the company’s history. And it’s got the receipts to show for it. |
By Fraiser Kansteiner Pfizer knows it had a bad year in 2023. Speaking to reporters at the 2024 J.P. Morgan Healthcare Conference on Monday, the company’s CEO, Albert Bourla, spoke bluntly about the hits the company took, and he acknowledged the underperformance of certain key launches. |
|
Wednesday, January 24, 2024 | 2pm ET / 11am PT Join industry experts to hear how digital collection of patient-reported outcomes (PROs) can lay the foundation for advancing health equity, which methods can ensure that PROs are relevant for diverse populations, and what challenges and opportunities still lie ahead. Register now.
|
|
By Annalee Armstrong,Max Bayer,Gabrielle Masson,James Waldron,Ben Adams Welcome to Day 2 of the J.P. Morgan Healthcare Conference 2024 in San Francisco. Yesterday Merger Monday lived up to its name with deals for Novartis, J&J and Merck, and today, we’re also starting the day with an early deal. Check out all the updates from JPM below. |
By Max Bayer Computing behemoth Nvidia is expanding its march into drug development, announcing a new partnership with Amgen's deCode and adding Recursion to its AI-based discovery platform. |
By Nick Paul Taylor Blueprint Medicines is pulling back from one of its three areas of focus, dropping two non-small cell lung cancer (NSCLC) programs in response to early clinical data on the EGFR tyrosine kinase inhibitors. |
By Kevin Dunleavy Two successful phase 3 trials put Astellas’ monoclonal antibody zolbetuximab on track to become the first approved therapy to treat one of the hottest targets in oncology—tumors that are claudin (CLDN) positive. But the Japanese company will have to clear up manufacturing issues first. The FDA has sent a complete response letter to Astellas, rejecting zolbetuximab because of unresolved deficiencies identified in a pre-license inspection of a third-party manufacturing facility. |
By Andrea Park Hot on the heels of the official launch of its artificial intelligence-focused initiative, Flagship Pioneering is debuting yet another advanced technology-centric project. |
By Zoey Becker With Novo Nordisk and Eli Lilly dominating the obesity field, Amgen's CEO Robert Bradway knows a new offering will have to offer a unique benefit. Amgen's phase 2 candidate MariTide, plus a myriad of preclinical assets, could stand out from the crowd with a differentiated approach, the CEO figures. |
By James Waldron The center, which will be based at the headquarters of Doudna’s own Innovative Genomics Institute (IGI), will be known as the Danaher-IGI Beacon for CRISPR Cures. |
By Andrea Park With an eye toward expanding the reach of its cancer diagnostics portfolio, Veracyte has made moves to pick up C2i Genomics, maker of tests to detect the minimal residual disease left behind after cancer treatments. |
Fierce podcastsDon’t miss an episode |
| | This week on "The Top Line," Fierce Biotech staff writer Gabrielle Masson and senior editor Annalee Armstrong look back at the year in biotech, which was defined by massive layoffs across the industry. They also discuss their favorite stories of the year, including an appearance from a popstar whose reputation precedes her. |
|
|---|
|
|
|
Stability and particle formation are key variables across the lifecycle. New instruments that improve measurement are transforming testing and becoming necessary. Download this essential reading now for biopharma companies that want to understand how particle detection is evolving and the value new technologies provide across the lifecycle.
|
|
| Whitepaper Discover how to effectively classify highly potent APIs and the steps required to develop containment protocols and manufacturing processes that are both safe and efficient. Sponsored by: Catalent |
| eBook This e-book explores 7 factors that are critical to the success of emerging biopharma companies, whether they plan to out-license, partner, or launch & commercialize products. It’s an essential resource for emerging companies with products in all stages of development.
Presented by Blue Matter, strategic consultants in the life sciences |
| WhitepaperThe road to digital health innovation is exciting but complex and requires thoughtful navigation; this whitepaper serves as your guide through this process. Sponsored by: S3 Connected Health |
| |
|
